Fig. 9

The immune landscape and the immunotherapy response of the DAMP-related signature. (A) Estimation of immune scores, stromal scores, tumor purity between low- and high-risk patients using the ESTIMATE algorithm. (B) Estimation of immune cell proportions in low- and high-risk patients using the ssGSEA algorithm. (C) Heat map demonstrating gene expression profiles of immune checkpoint genes, immuno-stimulator signature, cytolytic activity signature, and MHC family genes in low- and high-risk patients. (D) The TIDE score identifying immunotherapy response of patients in TCGA-LUAD cohort. (E) The TIDE score in low- and high-risk LUAD patients. (F) Comparison of AUC of immunotherapy biomarkers in several reported immunotherapy cohorts. (G) The ability of seven biomarkers to distinguish response or non-response patients with immunotherapy. Red line refers to p < 0.05. (H) OS probability in low- and high-risk patients of reported immunotherapy cohorts. P values were calculated using Wilcoxon rank sum test (*P < 0.05; **P < 0.01; ***P < 0.001, ****P < 0.0001)